Sirius Pintuition® – Moving from Localization to Surgical Marker Navigation
28 March 2023 – Eindhoven, Netherlands – Our portfolio company Sirius Medical, the leader in surgical marker navigation, today announced the successful closing of a Series B Round 12 M€. The funding will accelerate the worldwide growth of their product Pintuition and support further product development. Holland Capital acted as lead investor for this series B with support from existing investors BOM Brabant Ventures, Curie Capital, Team Holmium, and a major investment from Sirius Medical’s management and team. Norgine Ventures joined as a new investor in this round to support further commercial roll-out.
Sirius’ state-of-the-art navigation system Pintuition provides surgeons with real-time distance and directional navigational guidance to locate tumors easily and accurately. With over 100 active centers and more than 5,000 successful Pintuition procedures across Western Europe and the US, the company experienced an unprecedented growth in revenue in 2022, attributable to Pintuition’s ease of use, straightforward implementation, and its unmatched precision in locating the target tissue.
“Sirius Medical has done a great job developing and bringing to market the Pintuition technology with a strong commercial start”, says Peter Stein, Chief Executive of Norgine Ventures. “Norgine Ventures is excited to support Sirius Medical’s leadership and their vision to deliver cost effective solutions in surgery.”
“We are excited about the market potential for surgical marker navigation,” says Jan Frens van Giessel, partner at Holland Capital. “We believe that the Pintuition technology and its future innovations will significantly improve surgery of non-palpable tumors for patients, physicians and improve the care for cancer patients.”
“Having become the fastest growing company in the industry is a clear confirmation of the unique benefits that our technology brings to both patients and physicians,” says Bram Schermers, CEO at Sirius Medical. “Supported by this latest funding round I am confident that our highly talented and motivated team will further drive the adoption of Pintuition across the globe.”
About Sirius Medical
With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. The Pintuition technology is precise, simple, affordable and both CE marked, and FDA cleared. Sirius Medical is rapidly expanding with over 100 centers and an international sales network in Europe and the USA. www.sirius-medical.com
About Holland Capital
Over the past 40 years Holland Capital has responsibly and successfully invested in more than 160 SMEs. With a clear investment strategy Holland Capital is active in the attractive growth markets of Healthcare and Technology. Holland Capital’s experienced, entrepreneurial and committed investment team aims to establish an open, sustainable and professional relationship with the companies it invests in with the common goal of achieving growth. Holland Capital is backed by a broad network of successful Healthcare and Technology entrepreneurs.
De turbulente ondernemersloopbaan van Harald Swinkels (NLE) centraal tijdens Holland Venture Growth Session
Amsterdam, 10 april 2018 – Harald Swinkels (voormalig CEO Nederlandse Energie Maatschappij) deelde tijdens de vijfde Holland Venture Growth Session zijn ervaringen met de aanwezigen. In 2005 richtte Harald Swinkels, na eerdere ondernemersavonturen in onder meer de...
Inzet op innovatie werpt zijn vruchten af – Gilde Buy Out Partners stapt in als aandeelhouder Esdec
Amsterdam, 26 maart 2018 - Op 22 maart is Gilde Buy Out Partners toegetreden als nieuwe aandeelhouder in Esdec. Esdec ontwikkelt, produceert en levert professionele montagesystemen voor zonnepanelen op alle type daken. De snelle groei en het innovatieve karakter van...
DeltaScan eerste meetinstrument dat kans op delirium laat zien
DeltaScan op NOS journaal – primeur in UMC Utrecht ICU https://prolira.com/deltascan-op-nos-journaal-primeur-in-umc-utrecht-icu/ Utrecht, 8 maart 2018. Het UMC Utrecht en het bedrijf Prolira hebben een innovatief apparaat ontwikkeld om een delirium vast te stellen....
Avensus Groep zet met overname ICT Vision eerste stap in buy-and-build strategie
Amsterdam, 22 februari 2018 – Avensus Nederland, Participatiemaatschappij Holland Venture, Abram Schermer en Ed Trautig verstevigen de samenwerking middels de oprichting van Avensus Groep. Hiermee bouwen zij het partnership uit dat ze eind 2016 zijn aangegaan. De...
Holland Venture’s portfoliobedrijf Highcare investeert in opleidingsinstituut Latona
Amsterdam, 22 januari 2018 – Highcare, hét uitzend- en detacheringsbureau in de zorg en het veiligheidsdomein, heeft de activiteiten van Latona overgenomen. Latona levert organisatie- en opleidingsadvies diensten binnen de acute zorg. De afgelopen jaren heeft Highcare...
Holland Venture verstrekt groeifinanciering aan revalidatiekliniek Ortius
Amsterdam, 11 januari 2018 – Participatiemaatschappij Holland Venture verstrekt groeifinanciering aan Ortius, een vooruitstrevende kliniek op het gebied van medische specialistische pijnrevalidatie. De investering stelt Ortius in staat de geboden zorg verder te...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 311 94 11
Düsseldorf
Inselstraße 34
40479 Düsseldorf
+49 (0) 211 43 63 69 01
Contact
info@hollandcapital.nl